Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Capital Expenditures (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Capital Expenditures for 9 consecutive years, with $144000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 53.55% to $144000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 17.34% year-over-year, with the annual reading at $1.6 million for FY2025, 17.34% up from the prior year.
  • Capital Expenditures hit $144000.0 in Q4 2025 for Protagonist Therapeutics, down from $1.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.3 million in Q3 2025 to a low of -$442000.0 in Q2 2025.
  • Historically, Capital Expenditures has averaged $272500.0 across 5 years, with a median of $213000.0 in 2021.
  • Biggest five-year swings in Capital Expenditures: surged 1531.58% in 2024 and later plummeted 292.17% in 2025.
  • Year by year, Capital Expenditures stood at $196000.0 in 2021, then skyrocketed by 274.49% to $734000.0 in 2022, then tumbled by 97.41% to $19000.0 in 2023, then skyrocketed by 1531.58% to $310000.0 in 2024, then plummeted by 53.55% to $144000.0 in 2025.
  • Business Quant data shows Capital Expenditures for PTGX at $144000.0 in Q4 2025, $1.3 million in Q3 2025, and -$442000.0 in Q2 2025.